文献速递乳腺癌

围手术期T-DXd-THP对比ddAC-THP治疗高危HER2阳性早期乳腺癌的III期随机试验

Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel, trastuzumab, and pertuzumab for high-risk HER2-positive early breast cancer (DESTINY-Breast11): a randomised, open-label, multicentre, phase III trial.
PubMed 文献 · Ann Oncol · 2025-10-21

DESTINY-Breast11是一项开放标签、多中心III期试验,随机分配高危HER2阳性早期乳腺癌患者接受T-DXd单药、T-DXd序贯THP或ddAC序贯THP新辅助治疗。主要终点病理完全缓解率(pCR)在T-DXd-THP组为67.3%,显著优于ddAC-THP组的56.3%,绝对差异11.2%(95%CI 4.0-18.3,P=0.003)。T-DXd-THP组≥3级不良事件和严重不良事件发生率均低于ddAC-THP组。

要点

  • T-DXd-THP较ddAC-THP显著提高pCR率(67.3% vs 56.3%,绝对差异11.2%,P=0.003)。
  • HR阳性和HR阴性亚组中T-DXd-THP均显示pCR获益。
  • T-DXd-THP组≥3级AE和严重AE发生率低于ddAC-THP组。

核心结论

  • 新辅助T-DXd-THP对比ddAC-THP在高危HER2阳性早期乳腺癌中显示出统计学显著且具有临床意义的pCR获益,并改善安全性。

研究设计与样本

  • 开放标签、多中心、随机III期试验,在18个国家147个中心进行,按1:1:1随机分配至T-DXd(8周期)、T-DXd-THP(4+4周期)或ddAC-THP(4+4周期)组。
  • 入组高危(≥cT3cN0或cT0-4cN1-3)HER2阳性早期乳腺癌成人患者,主要终点为意向治疗人群的pCR(ypT0/is ypN0)。
  • T-DXd单药组在独立数据监查委员会建议后提前关闭入组。

主要发现

  • pCR率:T-DXd组43.0%(n=123),T-DXd-THP组67.3%(n=216),ddAC-THP组56.3%(n=180)。
  • T-DXd-THP对比ddAC-THP的pCR绝对差异为11.2%(95%CI 4.0-18.3,P=0.003)。
  • HR阳性亚组pCR率61.4% vs 52.3%(ΔpCR 9.1%,95%CI 0.2-17.9);HR阴性亚组83.1% vs 67.1%(ΔpCR 16.1%,95%CI 3.0-28.8)。
  • 中位EFS(T-DXd-THP vs ddAC-THP,成熟度4.5%)风险比为0.56(95%CI 0.26-1.17)。
  • ≥3级AE:T-DXd组22.6%(n=64),T-DXd-THP组37.5%(n=120),ddAC-THP组55.8%(n=174);严重AE分别为10.2%(n=29)、10.6%(n=34)、20.2%(n=63);全级别左心室功能障碍分别为0.7%(n=2)、1.3%(n=4)、6.1%(n=19);药物相关间质性肺病/肺炎分别为4.9%(n=14)、4.4%(n=14)、5.1%(n=16)。

关键数值与推荐

  • T-DXd-THP组pCR率67.3%,ddAC-THP组56.3%,绝对差异11.2%(95%CI 4.0-18.3,P=0.003)。
  • T-DXd单药组pCR率43.0%。
  • T-DXd-THP组≥3级AE发生率37.5%,低于ddAC-THP组的55.8%。

临床怎么用

  • 对于高危HER2阳性早期乳腺癌,新辅助T-DXd-THP方案较ddAC-THP显著提高pCR率且安全性更好,可能成为新的治疗选择。

局限性

  • T-DXd单药组因独立数据监查委员会建议提前关闭入组,可能影响该组结果的解读。
  • EFS数据成熟度低(4.5%),需更长期随访评估生存获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Neoadjuvant standard-of-care for HER2-positive early-stage breast cancer is trastuzumab + pertuzumab with polychemotherapy; however, existing regimens have high toxicity burdens and suboptimal outcomes. DESTINY-Breast11 assessed efficacy and safety of neoadjuvant trastuzumab deruxtecan (T-DXd) alone or followed by paclitaxel + trastuzumab + pertuzumab (THP) versus dose-dense doxorubicin + cyclophosphamide (ddAC) followed by THP for high-risk (≥cT3cN0 or cT0-4cN1-3) HER2-positive disease. PATIENTS AND METHODS: This open-label, phase III trial (147 sites, 18 countries) randomised adults 1 : 1 : 1 to T-DXd (×8 cycles), T-DXd-THP (4 + 4 cycles), or ddAC-THP (4 + 4 cycles). T-DXd-alone arm enrolment closed early following the Independent Data Monitoring Committee recommendation. The primary endpoint was pathological complete response (pCR; ypT0/is ypN0; intent-to-treat population). Secondary endpoints included event-free survival (EFS; intent-to-treat population) and safety (safety analysis set). RESULTS: Between 25 October 2021 and 12 March 2025, 286 (T-DXd), 321 (T-DXd-THP), and 320 (ddAC-THP) female patients were randomised. pCR rates were 43.0% (T-DXd, n = 123), 67.3% (T-DXd-THP, n = 216), and 56.3% (ddAC-THP, n = 180). T-DXd-THP versus ddAC-THP absolute pCR rate difference was 11.2% [95% confidence interval (CI), 4.0% to 18.3%, P = 0.003], with benefit in hormone receptor (HR)-positive [61.4% (n/N = 145/236) versus 52.3% (n/N = 123/235); difference in pCR (ΔpCR) 9.1% (95% CI 0.2% to 17.9%)] and HR-negative [83.1% (n/N = 69/83) versus 67.1% (n/N = 57/85); ΔpCR 16.1% (95% CI 3.0% to 28.8%)] subgroups. Median EFS (T-DXd-THP versus ddAC-THP, maturity 4.5%) hazard ratio was 0.56 (95% CI 0.26 to 1.17). Grade ≥3 adverse events (AE; T-DXd, 22.6% (n = 64); T-DXd-THP, 37.5% (n = 120); ddAC-THP, 55.8% (n = 174)], serious AE [T-DXd, 10.2% (n = 29); T-DXd-THP, 10.6% (n = 34); ddAC-THP, 20.2% (n = 63)], and all-grade left-ventricular dysfunction [T-DXd, 0.7% (n = 2); T-DXd-THP, 1.3% (n = 4); ddAC-THP, 6.1% (n = 19)] rates were lower for T-DXd and T-DXd-THP than ddAC-THP. All-grade adjudicated drug-related interstitial lung disease/pneumonitis rates were low and similar across arms [T-DXd, 4.9% (n = 14); T-DXd-THP, 4.4% (n = 14); ddAC-THP, 5.1% (n = 16)]. Three treatment-related deaths occurred [T-DXd-THP, 0.3% (n = 1); ddAC-THP, 0.6% (n = 2)]. CONCLUSIONS: Neoadjuvant T-DXd-THP demonstrated statistically significant and clinically meaningful pCR benefit and improved safety versus ddAC-THP.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Harbeck N, Modi S, Pusztai L, et al. Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel, trastuzumab, and pertuzumab for high-risk HER2-positive early breast cancer (DESTINY-Breast11): a randomised, open-label, multicentre, phase III trial. Ann Oncol. 2025. PMID: 41130363. doi:10.1016/j.annonc.2025.10.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。